Coloplast met expectations for growth for the 2006/07 financial year, reporting organic revenue growth of 10% against 8% last year. The company maintained the EBIT margin before non-recurring costs at 16% in a year dominated by extensive activity of integrating the acquired urology business, divesting businesses and relocating production to Hungary and China. EBIT was DKK 749m after non-recurring costs of DKK 552m, which included a goodwill writedown of DKK 283m (see enclosed PDF).
Attachments
